Bellerophon Therapeutics has completed enrollment of its 80-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart's right ventricle, eventually leading to heart failure.
PAH occurs when most of the very small arteries throughout the lungs narrow in diameter, increasing the resistance to blood flow through the lungs. To overcome the increased resistance, pressure increases in the pulmonary artery and the right ventricle -- the heart chamber that pumps blood into the pulmonary artery. In addition, PAH may cause changes to the blood vessel lining that hinders the natural production of nitric oxide.
Prior to the availability of current treatments, primary PAH patients had an average survival of less than three years. There are a number of drugs approved for the treatment of PAH that work by reducing vascular resistance. However, despite the availability of multiple therapies for this indication, the mortality rate for PAH patients remains high, with estimates of median survival ranging from three to five years.
Bellerophon's INOpulse device delivers brief, controlled pulses of nitric oxide, which is a selective, short-acting pulmonary vasodilator, that are inhaled by the patient. INOpulse is portable, allowing for treatment of ambulatory patients on daily basis outside the hospital. Nitric Oxide is naturally produced and released by portions of the blood vessels and results in smooth muscle relaxation. In particular, nitric oxide controls muscle tone in blood vessels and thus is an important factor in regulating blood pressure. As the muscles of the blood vessels relax, blood flow increases, helping the heart to deliver more blood to the body.
This Phase 2 study, being conducted at 52 sites in the United States and Canada, is a randomized, placebo-controlled trial of INOpulse as an add-on therapy for use in patients whose disease is progressing despite treatment with other PAH medications. The trial will determine the safety, tolerability and efficacy in this population of two different doses of INOpulse for PAH. The primary endpoint is a change in pulmonary vascular resistance at 16 weeks from baseline. Secondary endpoints include change in mean pulmonary arterial pressure and cardiac index as well as change in six-minute walk distance. The trial is expected to be completed by the end of 2014.
"The U.S. Food and Drug Administration has granted orphan drug designation for nitric oxide for the treatment of PAH, which will give us seven years of exclusivity in the U.S. if INOpulse is the first inhaled nitric oxide therapy approved in this indication," stated Daniel Tasse, interim chief executive officer of Bellerophon. "There is presently no cure for PAH and, despite several approved therapies, the mortality rate remains high. The completion of enrollment in this important Phase 2 trial is therefore a key milestone for Bellerophon, and we look forward to the continued development of this potential new first-in-class therapy."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- True Weight Loss Is Rare
- What May Be Missing From Quantum Computing - A Quantum Middle Man
- AMVA4NewPhysics Logo
- Genetic Testing In Kids - The Science Isn't Complicated But The Psychology Is
- Patients With Recurrent Depression Have Smaller Hippocampi
- Radiation Detectors Click By Design
- New GHOST Technology Leaps Out Of The Screen
- "Apologizing for a hiatus due to vacations, I am posting today.... Yes Tommaso, how dare you allow..."
- "Tommaso, I understand the message, and I 100% agree that more women in science is always better..."
- "Thanks for your thoughtful comments, Herne.And sharing your story, which has a lot of wrinkles..."
- "I think it's awesome that you kicked it three times and I do hope it stays off.I do think individuals..."
- "Hi Martin,I don't know if women appreciate pink, but it is indeed a stereotype - so a means for..."
- Opera is deadly - but The Tarantino influence in modern opera is killing it
- Gene therapy for cystic fibrosis shows encouraging trial results
- Prion trials and tribulations: Finding the right tools and experimental models
- Old World monkey had tiny, complex brain
- Rumors of southern pine deaths have been exaggerated